Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=27409915&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU8896(A)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/389,860external-prioritypatent/US20010051616A1/en
Application filed by Merck & Co. Inc.filedCriticalMerck & Co. Inc.
Publication of YU8896ApublicationCriticalpatent/YU8896A/sh
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Peptides Or Proteins
(AREA)
Abstract
Alendronat, jedan bisfosfonat, kada se primenjuje svakodnevno u toku bitnog perioda vremena, može da smanji razmeru kičmenih i ne-kičmenih preloma kod žena posle menopauze. Dalje, on može da smanji broj i ozbiljnost preloma. Isto tako, primena alendronata može da spreči deformitet kičme, i gubitak u visini.
YU8896A1995-02-171996-02-16Upotreba alendronata u proizvodnji leka za smanjenje rizika kičmenih i ne-kičmenih preloma
YU8896A
(sh)
The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
El uso de un compuesto potenciador de dopamina/reductor de prolactina para preparar composiciones para prevenir la estenosis asociada con intervencion despues de intervenciones invasivas sin derivacion.